Live news related to UCB stock (BE0003739530): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on UCB mainly cover analyst notes, M&A activity et guidance and outlook. The stock trades at €246,00 on Euronext Paris, up 1,23% at the last update. This page lists the articles published on UCB stock to track the share price, company announcements and any item likely to influence market perception.
UCB presented new clinical data at the International Congress on Neuromuscular Diseases (ICNMD) 2026, demonstrating that rozanolixizumab administered …
UCB: Two studies confirm the efficacy of Kygevvi in TK2d. The results document improvements in survival and function in treated patients, as well as t…
UCB announced on Wednesday the completion of its acquisition of Candid Therapeutics, a clinical-stage biotech specializing in T-cell engaging therapie…
UCB presented new mechanistic data on Cimzia (certolizumab pegol) at EULAR 2026 on Friday, showing that its lack of an Fc domain allows it to maintain…
UCB laboratories disclosed on Wednesday Phase 2/3 data and their open-label extensions regarding Bimzelx (bimekizumab) in the treatment of psoriatic a…
UCB announced on Tuesday the complete acquisition of Neurona Therapeutics and its drug candidate Rezanecel, a Phase I/II treatment for drug-resistant …
UCB announced on Tuesday its research on thymidine kinase 2 deficiency (TK2d), an ultra-rare disease, at the EUROMIT 2026 conference. The data highlig…
UCB and Biogen announced on Monday the publication in The Lancet of the phase 3 results of dapirolizumab pegol (DZP) in the treatment of systemic lupu…
UCB announced on Tuesday data from the BE BOLD trial confirming the clinical superiority of Bimzelx (bimekizumab) over Skyrizi (risankizumab) in the t…
UCB SA has announced the convening of its ordinary and extraordinary general meeting on April 30, 2026. The pharmaceutical group will submit for share…
